Login
$VNDA
$3.81 -$0.18 (4.51%) Live

$VNDA SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 Form 4: Duncan Charles Cliff, Director

Bought 750 shares ($2.85K) · Bought 3,447 shares ($13.2K) · Bought 5,803 shares ($22.1K)

29 Oct 2026 10-Q
28 Oct 2026 8-K: Results of Operations and Financial Condition

WASHINGTON – October 28, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026.

27 Oct 2026 SCHEDULE 13G
09 Oct 2026 SCHEDULE 13G/A
19 Aug 2026 SCHEDULE 13G
13 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

WASHINGTON – August 5, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026.

08 Jun 2026 Form 4: McGuire Daniel Patrick, SVP, GC and Secretary

Received 80,000 shares as a grant or award

08 Jun 2026 Form 4: Chrousos Phaedra, Director

Received 41,600 shares as a grant or award

08 Jun 2026 Form 4: Duncan Charles Cliff, Director

Received 41,600 shares as a grant or award

08 Jun 2026 Form 4: Dugan Richard W, Director

Received 41,600 shares as a grant or award

08 Jun 2026 Form 4: Ward Anne Sempowski, Director

Received 41,600 shares as a grant or award

08 Jun 2026 Form 4: Honore Tage, Director

Received 41,600 shares as a grant or award

08 Jun 2026 Form 4: Mitchell Stephen Ray, Director

Received 41,600 shares as a grant or award

08 Jun 2026 Form 3: McGuire Daniel Patrick, SVP, GC and Secretary

Holds 1,732 shares of Common Stock

05 Jun 2026 S-8

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support